Kala Historical Balance Sheet

KALA Stock

USD 8.38 0.62 7.99%

Trend analysis of Kala Pharmaceuticals balance sheet accounts such as Other Liab of 5.1 M provides information on Kala Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Kala Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Kala Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Yuan Drop

Covid

Financial Statement Analysis is much more than just reviewing and examining Kala Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Kala Pharmaceuticals is a good buy for the upcoming year.

Kala Pharmaceuticals Inventory

5.55 Million

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

About Kala Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Kala Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Kala Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Kala Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Kala currently owns. An asset can also be divided into two categories, current and non-current.

Kala Pharmaceuticals Balance Sheet Chart

At present, Kala Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 18 M, whereas Total Stockholder Equity is forecasted to decline to about 8.2 M.

Total Assets Total Current Liabilities Other Liab Accounts Payable Other Current Assets Net Working Capital

Add Fundamental

Total Assets

Total assets refers to the total amount of Kala Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Kala Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Kala Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Kala Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents Kala Pharmaceuticals obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Kala Pharmaceuticals are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Other Current Assets

Assets expected to be converted into cash, sold, or consumed either in one year or in the operating cycle, which are not included under standard current asset categories.

Most accounts from Kala Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Kala Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Kala Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.At present, Kala Pharmaceuticals' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Current Liabilities is expected to grow to about 18 M, whereas Total Stockholder Equity is forecasted to decline to about 8.2 M.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	25.7M	8.3M	9.6M	18.0M
Total Assets	86.8M	55.9M	64.3M	116.8M

Total Current Liabilities Total Assets

Kala Pharmaceuticals balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Other Liab	Net Tangible Assets	Retained Earnings	Accounts Payable	Cash	Other Assets	Long Term Debt	Net Receivables	Common Stock Shares Outstanding	Other Current Assets	Total Liab	Short Long Term Debt	Total Current Assets	Short Term Debt	Common Stock	Property Plant Equipment	Short Long Term Debt Total	Other Current Liab	Property Plant And Equipment Net	Net Debt	Non Current Assets Total	Non Currrent Assets Other	Cash And Short Term Investments
Total Assets		0.76	0.88	0.78	0.87	-0.46	0.77	0.89	0.75	0.89	0.57	-0.02	0.39	0.74	-0.08	0.99	-0.34	0.79	0.68	0.93	0.7	0.82	-0.29	0.84	0.79	0.97
Total Current Liabilities	0.76		0.61	0.77	0.6	-0.66	0.63	0.68	0.5	0.87	0.87	0.11	0.79	0.69	0.16	0.78	-0.25	0.76	0.4	0.8	0.95	0.45	-0.13	0.54	0.64	0.7
Total Stockholder Equity	0.88	0.61		0.6	1.0	-0.42	0.65	0.85	0.61	0.7	0.36	0.02	0.33	0.37	0.22	0.9	-0.05	0.66	0.54	0.75	0.51	0.67	-0.43	0.67	0.63	0.91
Other Liab	0.78	0.77	0.6		0.63	-0.8	0.65	0.65	0.56	0.95	0.61	0.47	0.59	0.72	-0.02	0.75	-0.65	0.57	0.54	0.92	0.74	0.65	0.05	0.68	0.66	0.71
Net Tangible Assets	0.87	0.6	1.0	0.63		-0.48	0.63	0.85	0.59	0.71	0.34	0.1	0.34	0.37	0.23	0.89	-0.1	0.63	0.51	0.75	0.5	0.65	-0.43	0.65	0.6	0.91
Retained Earnings	-0.46	-0.66	-0.42	-0.8	-0.48		-0.28	-0.43	-0.22	-0.66	-0.42	-0.74	-0.75	-0.45	-0.27	-0.5	0.5	-0.25	-0.01	-0.55	-0.56	-0.14	0.05	-0.17	-0.22	-0.47
Accounts Payable	0.77	0.63	0.65	0.65	0.63	-0.28		0.84	0.38	0.75	0.44	-0.19	0.38	0.65	-0.41	0.77	-0.39	0.56	0.77	0.76	0.59	0.68	-0.41	0.68	0.87	0.75
Cash	0.89	0.68	0.85	0.65	0.85	-0.43	0.84		0.37	0.74	0.36	-0.02	0.36	0.62	-0.14	0.92	-0.33	0.59	0.63	0.76	0.56	0.61	-0.66	0.61	0.73	0.94
Other Assets	0.75	0.5	0.61	0.56	0.59	-0.22	0.38	0.37		0.68	0.59	-0.13	0.19	0.56	0.05	0.68	-0.14	0.78	0.47	0.74	0.56	0.79	0.27	0.85	0.59	0.64
Long Term Debt	0.89	0.87	0.7	0.95	0.71	-0.66	0.75	0.74	0.68		0.75	0.22	0.56	0.78	-0.01	0.86	-0.54	0.79	0.65	0.98	0.87	0.75	-0.02	0.8	0.8	0.8
Net Receivables	0.57	0.87	0.36	0.61	0.34	-0.42	0.44	0.36	0.59	0.75		-0.09	0.61	0.62	0.21	0.55	-0.16	0.82	0.39	0.69	0.96	0.47	0.22	0.58	0.58	0.43
Common Stock Shares Outstanding	-0.02	0.11	0.02	0.47	0.1	-0.74	-0.19	-0.02	-0.13	0.22	-0.09		0.33	-0.03	0.3	0.01	-0.43	-0.22	-0.29	0.14	0.03	-0.19	0.18	-0.2	-0.18	0.02
Other Current Assets	0.39	0.79	0.33	0.59	0.34	-0.75	0.38	0.36	0.19	0.56	0.61	0.33		0.39	0.23	0.45	-0.07	0.33	-0.02	0.44	0.68	0.04	-0.06	0.11	0.29	0.37
Total Liab	0.74	0.69	0.37	0.72	0.37	-0.45	0.65	0.62	0.56	0.78	0.62	-0.03	0.39		-0.45	0.72	-0.69	0.58	0.54	0.76	0.68	0.61	-0.11	0.65	0.63	0.69
Short Long Term Debt	-0.08	0.16	0.22	-0.02	0.23	-0.27	-0.41	-0.14	0.05	-0.01	0.21	0.3	0.23	-0.45		-0.05	0.49	0.13	-0.29	-0.05	0.17	-0.19	0.17	-0.14	-0.29	-0.1
Total Current Assets	0.99	0.78	0.9	0.75	0.89	-0.5	0.77	0.92	0.68	0.86	0.55	0.01	0.45	0.72	-0.05		-0.31	0.77	0.6	0.88	0.7	0.73	-0.4	0.76	0.77	0.99
Short Term Debt	-0.34	-0.25	-0.05	-0.65	-0.1	0.5	-0.39	-0.33	-0.14	-0.54	-0.16	-0.43	-0.07	-0.69	0.49	-0.31		-0.12	-0.33	-0.49	-0.28	-0.33	-0.03	-0.32	-0.36	-0.32
Common Stock	0.79	0.76	0.66	0.57	0.63	-0.25	0.56	0.59	0.78	0.79	0.82	-0.22	0.33	0.58	0.13	0.77	-0.12		0.5	0.77	0.85	0.65	-0.01	0.74	0.82	0.69
Property Plant Equipment	0.68	0.4	0.54	0.54	0.51	-0.01	0.77	0.63	0.47	0.65	0.39	-0.29	-0.02	0.54	-0.29	0.6	-0.33	0.5		0.75	0.43	0.9	-0.1	0.87	0.69	0.58
Short Long Term Debt Total	0.93	0.8	0.75	0.92	0.75	-0.55	0.76	0.76	0.74	0.98	0.69	0.14	0.44	0.76	-0.05	0.88	-0.49	0.77	0.75		0.78	0.86	-0.01	0.89	0.8	0.84
Other Current Liab	0.7	0.95	0.51	0.74	0.5	-0.56	0.59	0.56	0.56	0.87	0.96	0.03	0.68	0.68	0.17	0.7	-0.28	0.85	0.43	0.78		0.49	0.03	0.59	0.71	0.59
Property Plant And Equipment Net	0.82	0.45	0.67	0.65	0.65	-0.14	0.68	0.61	0.79	0.75	0.47	-0.19	0.04	0.61	-0.19	0.73	-0.33	0.65	0.9	0.86	0.49		0.06	0.99	0.71	0.71
Net Debt	-0.29	-0.13	-0.43	0.05	-0.43	0.05	-0.41	-0.66	0.27	-0.02	0.22	0.18	-0.06	-0.11	0.17	-0.4	-0.03	-0.01	-0.1	-0.01	0.03	0.06		0.1	-0.19	-0.47
Non Current Assets Total	0.84	0.54	0.67	0.68	0.65	-0.17	0.68	0.61	0.85	0.8	0.58	-0.2	0.11	0.65	-0.14	0.76	-0.32	0.74	0.87	0.89	0.59	0.99	0.1		0.75	0.72
Non Currrent Assets Other	0.79	0.64	0.63	0.66	0.6	-0.22	0.87	0.73	0.59	0.8	0.58	-0.18	0.29	0.63	-0.29	0.77	-0.36	0.82	0.69	0.8	0.71	0.71	-0.19	0.75		0.73
Cash And Short Term Investments	0.97	0.7	0.91	0.71	0.91	-0.47	0.75	0.94	0.64	0.8	0.43	0.02	0.37	0.69	-0.1	0.99	-0.32	0.69	0.58	0.84	0.59	0.71	-0.47	0.72	0.73

Click cells to compare fundamentals

Kala Pharmaceuticals Account Relationship Matchups

Kala Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	221.6M	139.4M	86.8M	55.9M	64.3M	116.8M
Total Current Liabilities	22.2M	37.4M	25.7M	8.3M	9.6M	18.0M
Total Stockholder Equity	100.0M	16.8M	19.0M	7.5M	8.6M	8.2M
Net Tangible Assets	29.7M	100.0M	16.8M	19.0M	21.8M	21.4M
Retained Earnings	(399.8M)	(542.4M)	(587.2M)	(629.4M)	(566.5M)	(538.1M)
Accounts Payable	1.7M	2.8M	2.3M	919K	1.1M	1.0M
Cash	77.3M	92.1M	70.5M	50.9M	58.5M	79.6M
Other Assets	16.4M	47.1M	11.0M	462K	531.3K	504.7K
Long Term Debt	72.2M	78.9M	37.9M	34.2M	39.3M	43.8M
Net Receivables	9.9M	17.5M	6.5M	236K	271.4K	257.8K
Common Stock Shares Outstanding	1.0M	1.3M	1.5M	2.4M	2.8M	2.9M
Other Current Assets	2.8M	6.1M	9.0M	1.7M	2.0M	2.5M
Total Liab	121.6M	122.6M	67.8M	48.4M	55.7M	91.9M
Total Current Assets	171.4M	124.4M	85.9M	52.9M	60.8M	98.6M
Short Term Debt	3.1M	1.4M	5.0M	334K	300.6K	285.6K
Common Stock	59K	66K	2K	3K	3.5K	3.3K
Property Plant Equipment	32.5M	9.4M	4.0M	416K	478.4K	454.5K
Short Long Term Debt Total	100.9M	80.2M	43.0M	36.3M	41.8M	61.0M
Other Current Liab	17.4M	33.2M	14.1M	6.0M	6.9M	6.6M
Property Plant And Equipment Net	31.0M	4.0M	416K	2.8M	3.2M	3.0M
Net Debt	23.7M	(11.9M)	(27.5M)	(14.6M)	(16.8M)	(17.6M)
Non Current Assets Total	50.2M	15.1M	878K	3.1M	3.5M	3.4M
Non Currrent Assets Other	6.2M	9.6M	462K	301K	346.2K	328.8K
Cash And Short Term Investments	153.5M	92.1M	70.5M	50.9M	58.5M	96.5M
Liabilities And Stockholders Equity	221.6M	139.4M	86.8M	55.9M	64.3M	128.3M
Non Current Liabilities Total	99.4M	85.2M	42.2M	40.1M	36.1M	59.2M
Other Stockholder Equity	499.7M	559.1M	606.2M	636.9M	732.4M	373.2M
Property Plant And Equipment Gross	31.0M	6.9M	1.6M	3.9M	4.5M	4.2M
Non Current Liabilities Other	27.1M	4.8M	4.2M	4.1M	3.7M	3.5M
Inventory	4.6M	5.2M	8.6M	7.7M	8.8M	5.6M
Net Invested Capital	172.2M	95.7M	61.9M	41.7M	37.5M	35.6M
Net Working Capital	149.2M	86.9M	60.3M	44.5M	40.1M	78.0M
Capital Lease Obligations	28.7M	1.3M	13K	2.1M	1.9M	1.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

CSX	CSX Corporation
ETON	Eton Pharmaceuticals
ALLT	Allot Communications

When determining whether Kala Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Kala Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Kala Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Kala Pharmaceuticals Stock:

How To Invest In Kala

Details

Is Kala Stock a good investment?

Details

What is Kala Pharmaceuticals' Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

For information on how to trade Kala Stock refer to our How to Trade Kala Stock guide.

You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Kala Pharmaceuticals. If investors know Kala will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Kala Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(11.67)

Quarterly Revenue Growth

(1.00)

Return On Assets

(0.44)

Return On Equity

(4.31)

The market value of Kala Pharmaceuticals is measured differently than its book value, which is the value of Kala that is recorded on the company's balance sheet. Investors also form their own opinion of Kala Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Kala Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Kala Pharmaceuticals' market value can be influenced by many factors that don't directly affect Kala Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Kala Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Kala Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Kala Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Kala Historical Balance Sheet

Kala Pharmaceuticals Inventory

5.55 Million

About Kala Balance Sheet Analysis

Kala Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Other Current Assets

Kala Pharmaceuticals balance sheet Correlations

Kala Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Kala Pharmaceuticals balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Tangible Assets	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 0.99	Total Assets
Cash And Short Term Investments	+ 0.99	Total Current Assets
Non Current Assets Total	+ 0.99	Property Plant And Equipment Net
Short Long Term Debt Total	+ 0.98	Long Term Debt
Cash And Short Term Investments	+ 0.97	Total Assets

Retained Earnings	- 0.8	Other Liab
Other Current Assets	- 0.75	Retained Earnings
Common Stock Shares Outstanding	- 0.74	Retained Earnings
Short Term Debt	- 0.69	Total Liab
Net Debt	- 0.66	Cash
Long Term Debt	- 0.66	Retained Earnings